3Craddock C, Augustson B, Basu S. lmatinib or transplant for chronic myeloid leukaemia? Lancet, 2003,362 : 173.
4Helmann R, Berger U, Engekich G, lmatinib Combinatlontherapien-the new CML-Study Ⅳ. Dtseh Med Wochenschr, 2002,127:224-226.
5Helmann R. Current CML therapy: progress and dilemma.Leukemia, 2003,1010-1012.
6Talpaz M,Siliver RT,Druker BJ,et al. lmatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood,2002,99:1928-1937.
7Ohno R, Nakamura Y. Prediction of response to imatinib by cDNA microarray analysis. Semin Hematol, 2003,40 (suppl 2) :42-49.
8Lange T, Gunther C, Kohler T. et al. High levels of BAX,low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.Blood,2003,101 : 2152-2155.
9Lewalle P, Meuleman N, Verhest A, et al. Infusion of peripheral blood stem cells collected at diagnosis, with maintenance of the treatment, resulted in Ph negative recovery in a chronic myeloid leukaemia patient in persisting aplasia on STI-571 therapy. Br J Haematol,2002,118: 144-146.
10Hui CH, Goh KY, White D, et al. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia,2003,17~821-828.
